Single-pill Therapy Achieves Better Long-term Blood Pressure Control
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A four-year randomized trial across 40 primary care clinics in Jamaica and Colombia found that a single-pill combination strategy controlled blood pressure better than usual stepped care. The approach also retained benefits after the trial ended, though the study did not establish effects on outcomes such as heart attacks or strokes.

A four-year randomized trial in Jamaica and Colombia found that patients with uncontrolled high blood pressure achieved better control when treated with two or three medicines combined in one pill than with usual stepped care, according to findings presented at the 2026 American Heart Association Scientific Sessions and published in JAMA. The results address whether the approach can work over the longer term, beyond the short trials that have informed earlier evidence.

Gift ideaOffer from Amazon

Give the gift of listening to someone you love

  • Choose a 1-, 3-, 6- or 12-month membership
  • They pick the audiobooks they love
  • Easy to send by email
Give Audible Delivered by email · No shipping needed
As an affiliate, we earn on qualifying purchases.

The Caribbean and South American Team-Based Strategy to Control Hypertension (CATCH) trial enrolled 1,706 patients at 40 primary care clinics. Clinics were assigned to one of two approaches. In the usual-care clinics, treatment mainly followed “stepped care”: patients began with one blood pressure medicine, with clinicians increasing doses or adding drugs when pressure remained high. In intervention clinics, patients received a single pill containing two or three antihypertensive medicines.

The intervention also included home blood pressure monitoring with equipment supplied by the study, regular review of readings by nurses, and coaching intended to support medication adherence. The comparison was therefore between care strategies, not simply between one pill and several pills in isolation.

At 18 months, average systolic pressure—the upper number in a reading—had fallen by about 19 points in the single-pill group, compared with about nine points in the usual-care group. Nearly 70% of patients in the intervention group reached the study target of systolic pressure below 130 mm Hg and diastolic pressure below 80 mm Hg; the corresponding share in usual care was 29%. Six months after the trial ended, 75% of intervention patients were still receiving the combination treatment through insurance or government programs and had maintained better control, the report said.

At a glance
reportWhen: Presented and published in November 202…
The developmentA four-year trial reported that single-pill combinations of blood pressure medicines outperformed usual care in Jamaica and Colombia, with better control persisting after the intervention.

A Longer Test of Combination Treatment

The findings matter because high blood pressure is a major preventable risk factor for cardiovascular disease, stroke, chronic kidney disease and other serious outcomes. Yet control remains limited: the source report cites estimates that blood pressure is controlled in 22.5% of U.S. patients with hypertension and 13.6% in low- and middle-income countries.

Putting several medicines into one pill may simplify a regimen, while the trial’s coaching and monitoring supported patients in taking treatment and tracking results. The study authors said the results support the feasibility of delivering this model in resource-constrained settings. The data also offer longer-term evidence that may inform care in the United States and elsewhere, but the trial tested blood pressure control—not whether the strategy reduces heart attacks, strokes or deaths.

The persistence of treatment after the study ended is relevant to whether a program can be maintained in routine care. Still, the reported six-month follow-up shows continued use among a share of participants; it does not establish that the same level of access or control would be sustained indefinitely or in every health system.

Products Worth Considering

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

As an affiliate, we earn on qualifying purchases.

Why Long-Term Evidence Was Needed

Clinical guidelines in the United States and internationally recommend single-pill combination therapy as a preferred strategy for many patients with high blood pressure. Earlier trials had found that combined medicines could lower blood pressure more quickly or effectively than multi-pill regimens, while the single-pill format can be more convenient. However, according to Jiang He, the previous trials were often short, leaving uncertainty about long-term effectiveness.

The CATCH trial was designed to address that gap through a four-year study conducted in primary care clinics in Jamaica and Colombia. Its results were presented in a late-breaking science session at the 2026 American Heart Association Scientific Sessions and published concurrently in JAMA. The study received funding from the U.S. National Heart, Lung, and Blood Institute.

The report also notes that only about 10% of U.S. patients with hypertension are treated with single-pill combinations. He cited physician unfamiliarity and a shortage of large, long-term trials as possible reasons the approach has not been more widely adopted, despite guideline recommendations.

“Our study demonstrated that a single-pill combination provided an effective, implementable, scalable, and sustainable approach for hypertension control in low- and middle-income countries.”

— Jiang He, co-leader of the CATCH trial and professor at UT Southwestern Medical Center

Questions Beyond Blood Pressure Readings

The reported results establish differences in blood pressure control, but the source does not report whether the intervention reduced heart attacks, strokes, kidney complications or deaths. Those clinical outcomes remain an important evidence gap identified by the study’s co-leader.

The trial compared a package of care—including the combination pill, home monitoring, nurse reviews and adherence coaching—with usual stepped care. The available report does not isolate how much of the difference came from the pill formulation versus the added support. It also does not provide detailed results on adverse effects, costs, or whether outcomes differed by patient characteristics.

Although 75% of intervention patients were still receiving the combination treatment six months after the trial ended, the report does not establish how long that continuation lasted beyond the follow-up period. Broader applicability to health systems outside Jamaica and Colombia also remains to be tested.

Further Trials and Wider Adoption

The published CATCH results add long-term evidence on blood pressure outcomes, but the researchers say additional large trials are needed to assess clinical outcomes and support decisions by clinicians and patients. Wider use will also depend on whether combination medicines are available, affordable and suited to individual patients in different health systems.

For now, the study supports the single-pill approach as part of a team-based care strategy in the settings studied. The next key evidence will be whether similar results can be reproduced elsewhere and whether improved blood pressure control translates into fewer major complications over time.

Key Questions

What did the CATCH trial compare?

It compared a single pill containing two or three blood pressure medicines, paired with home monitoring and adherence support, against usual care that mainly used stepped treatment with separate medicines added or adjusted over time.

How many patients took part, and where?

The trial enrolled 1,706 patients with uncontrolled hypertension at 40 primary care clinics in Jamaica and Colombia.

How much better was blood pressure control?

At 18 months, average systolic pressure fell by about 19 points in the single-pill group and nine points in usual care. Nearly 70% of the intervention group met the study’s target, compared with 29% of the usual-care group.

Does the trial show that the treatment prevents heart attacks or strokes?

The report describes improved blood pressure control, but does not establish effects on heart attacks, strokes or deaths. The study’s co-leader called for further trials examining these clinical outcomes.

Did patients keep using the combination treatment after the trial?

Six months after the trial ended, 75% of patients in the intervention group were still receiving the single-pill treatment through insurance or government programs and had maintained better blood pressure control, according to the report. Longer-term continuation was not reported.

Source: news-medical.net

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Cases Of High-risk Malaria Strain In Mumbai Jump 535% In 10 Years To 2,382 – The Times Of India

Mumbai reports a 535% increase in high-risk malaria strain cases over a decade, reaching 2,382. The trend raises public health concerns amid rising vector-borne diseases.

Could Hidden Belly Fat Tell Me About My Brain Health?

A personal DEXA scan prompts a closer look at visceral fat, blood pressure and dementia risk. The evidence does not show that belly fat predicts brain health on its own.

Inside The Lab Of A Parkinson’s Researcher Investigating The RAB32 Gene

Jay Penney’s team is using human stem-cell-derived brain cells to investigate how a rare RAB32 variant may contribute to Parkinson’s disease.